Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;72(5):742-747.
doi: 10.1097/MPG.0000000000003078.

Venous Thromboembolism in Pediatric Inflammatory Bowel Disease: A Case-Control Study

Affiliations

Venous Thromboembolism in Pediatric Inflammatory Bowel Disease: A Case-Control Study

Elana B Mitchel et al. J Pediatr Gastroenterol Nutr. .

Abstract

Objectives: Inflammatory bowel disease (IBD) is associated with increased risk of venous thromboembolism (VTE). Despite this recognized risk, there are limited data and no anticoagulation guidelines for hospitalized pediatric IBD patients. The objectives of this study were to characterize pediatric IBD patients with VTE and determine risk factors.

Methods: This was a nested case-control study comparing hospitalized children with IBD diagnosed with VTE to those without VTE over a decade at a large referral center. Standard descriptive statistics were used to describe the VTE group. Multivariable conditional logistic regression was used to assess risk factors.

Results: Twenty-three cases were identified. Central venous catheter (CVC) presence (odds ratio [OR] 77.9; 95% confidence interval [CI]: 6.9--880.6; P < 0.001) and steroid use (OR 12.7; 95% CI: 1.3--126.4; P = 0.012) were independent risk factors. Median age at VTE was 17 years (interquartile range [IQR] 13.5--18.2), and in 48%, VTE was the indication for admission. Median duration of anticoagulation was 3.8 months (IQR 2.3--7.6), and there were no major bleeding events for patients on anticoagulation. There were no patients with known sequelae from VTE, though 22% had severe VTE that required interventions.

Conclusions: Pediatric patients with IBD are at risk for VTE, although the absolute risk remains relatively low. The safety and efficacy of pharmacologic thromboprophylaxis needs to be further evaluated in this population with attention to risk factors, such as steroid use and presence of CVC.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interests.

Figures

FIGURE 1.
FIGURE 1.
Location of venous thromboembolism in the 23 cases. *Single patient could have more than 1 clot location.

References

    1. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism andits impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272–80. - PubMed
    1. Grainge MJ, West J, Card TR. Venous thromboembolism during activedisease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657–63. - PubMed
    1. Faye AS, Wen T, Ananthakrishnan AN, et al. Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;18:1133.e3–41.e3. - PMC - PubMed
    1. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–23. - PubMed
    1. Guyatt GH, Akl EA, Crowther M, et al., American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl): 7S–47S. - PMC - PubMed

Publication types